Covid-19 roundup: Mod­er­na of­fers vac­cine to work­ers, con­trac­tors and board mem­bers; Claim­ing 79% vac­cine ef­fi­ca­cy, Sinopharm shoots for full Chi­na OK

Mod­er­na is mov­ing its peo­ple — work­ers, con­trac­tors as well as board mem­bers — to the front of the vac­cine line in the US, of­fer­ing them a chance to get their two shots un­der emer­gency use au­tho­riza­tion.

The move will pro­vide an ad­di­tion­al lay­er of Covid-19 pro­tec­tion, the Cam­bridge, MA-based biotech said, as its staff is con­duct­ing es­sen­tial ser­vices in de­vel­op­ing, man­u­fac­tur­ing and de­liv­er­ing a vac­cine that pro­tects against the dis­ease caused by coro­n­avirus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.